Halozyme (HALO) Receives a Buy from Cantor Fitzgerald


Cantor Fitzgerald analyst Charles Duncan maintained a Buy rating on Halozyme (NASDAQ: HALO) today and set a price target of $27. The company’s shares opened today at $15.54.

Duncan said:

“We are OW with a $27 PT. The ENHANZE partnerships have recently expanded & include multiple shots on goal, with the reformulation of JNJ’s DARZALEX in P3 studies being most advanced. We believe these partnerships represent multiple value inflection points and, almost irrespective of the outcome of PC, drive our favorable perspective.”

According to TipRanks.com, Duncan is a 1-star analyst with an average return of -0.5% and a 42.6% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, KalVista Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Halozyme with a $21.67 average price target.

See today’s analyst top recommended stocks >>

Halozyme’s market cap is currently $2.19B and has a P/E ratio of 29.23. The company has a Price to Book ratio of 8.60.

Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Halozyme Therapeutics, Inc. is a biopharmaceutical company specializes in research, development, and commercialization of human enzymes and other drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts